

MasterClass in Bladder Cancer 2026

June 9th

Centro de Formación
y Simulación Avanzada,
Hospital Universitario 12 de Octubre
Avda. de Córdoba, s/n. Madrid

Scientific coordinators:

Dr. Daniel Castellano

Medical Oncology Department,
Hospital Universitario 12 de Octubre, Madrid

Dr. Félix Guerrero

Urology Department,
Hospital Universitario 12 de Octubre, Madrid

Format:

– In person –

INSCRIPCIONES AQUÍ

Organized by:

HENDERE HEALTHCARE

X #BladderMasterClass26



Hospital Universitario
12 de Octubre



June 9th, 2026

11:00 - 12:00 **Registration**

12:00 - 12:15 **Welcome**

Dr. Alfredo Rodríguez, Head of the Urology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Luis Paz-Ares, Head of the Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid

12:15 - 12:30 **Introduction**

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

12:30 - 12:45 **Keynote lecture – Danae Urogenomics: past, present and future**

Chair:

Dr. Javier Puente, Medical Oncology Department, Hospital Clínico San Carlos, Madrid

Speaker:

Dra. Marta Dueñas, CIEMAT - Hospital Universitario 12 de Octubre, Madrid

12:45 - 13:55 **Session 1 – High-Risk Non-Muscle-Invasive Bladder Cancer**

Chairs:

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Mario Álvarez, Urology Department, Hospital Universitario La Paz, Madrid

12:45 - 12:55 **BCG monotherapy is here to stay**

Dr. José Luis Domínguez, Urology Department, Instituto Valenciano de Oncología, Valencia

12:55 - 13:05 **Systemic immunotherapy is the future**

Dr. Óscar Rodríguez Faba, Urology Department, Fundació Puigvert, Barcelona

13:05 - 13:15 **Other intravesical therapies will be the winners**

Dr. Evangelos Xylinas, Urology Department, Hôpital Bichat Claude-Bernard, Paris, France

13:15 - 13:55 **Discussion with a clinical case**

Dr. Mario Hernández, Urology Department, Hospital Universitario 12 de Octubre, Madrid

13:55 - 14:15 **Keynote lecture – The role of molecular biology in personalizing perioperative treatment**

Chair:

Dra. Elena Sevillano, Medical Oncology Department, Centro Integral Oncológico Clara Campal HM CIOCC, Madrid

Speaker:

ONLINE **Dr. Bishoy Faltas**, Weill Cornell University, New York, USA

14:15 - 15:15

 **Lunch**



June 9th, 2026

15:15 - 16:25

Session 2 – Perioperative treatment in localized muscle-invasive bladder cancer: what should I choose?

Chairs:

Dr. Laura S. Mertens, Urology Department, Netherlands Cancer Institute (NKI), Antoni van Leeuwenhoek Hospital Amsterdam, Países Bajos

Dr. Fernando Lozano, Urology Department, Hospital Universitari Vall d'Hebron, Barcelona

15:15 - 15:25

Multiparametric MRI for clinical decision making, do we really need TURBT?

Dr. Albert Carrión, Urology Department, Hospital Universitari Vall d'Hebron, Barcelona

15:25 - 15:35

Neoadjuvant/perioperative therapy is the best option

Dr. Jose Daniel Subiela, Urology Department, Hospital Universitario 12 de Octubre, Madrid

15:35 - 15:45

Adjuvant therapy (guided by liquid biopsy?) is the best option

Dr. Álvaro Pinto, Medical Oncology Department, Hospital Universitario La Paz, Madrid

15:45 - 16:25

Discussion with a clinical case

Dra. Carmen Gómez del Cañizo, Servicio de Urología, Hospital Universitario 12 de Octubre, Madrid

16:25 - 16:45

Bonus track – Bladder sparing options: past, present and future

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

16:45 - 16:55

Discussion

16:55 - 17:30

Coffee break

17:30 - 19:10

Session 3 – Metastatic urothelial carcinoma: the current landscape

Chairs:

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

Dr. Guillermo de Velasco, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid

17:30 - 17:40

Enfortumab vedotin + pembrolizumab is the standard

Dra. María José Juan, Medical Oncology Department, Instituto Valenciano de Oncología, Valencia

17:40 - 17:50

Chemotherapy and immunotherapy are the standard

Dr. Enrique Grande, Medical Oncology Department, Hospital Universitario Quirónsalud, Madrid

17:50 - 18:00

How do these treatments impact subsequent lines of therapy?

Dr. Patrizia Giannatempo, Istituto Nazionale dei Tumori, Milán (Italia)

18:00 - 18:40

Discussion with a clinical case

Dr. Jorge Esteban, Medical Oncology Department, Hospital Universitario 12 de Octubre, Madrid



June 9th, 2026

18:40 - 19:00

Bonus track – New molecules and mechanisms of action in preclinical development

Dr. Ignacio Durán, Medical Oncology Department, Hospital Universitario Marqués de Valdecilla
- IDIVAL, Santander

19:00 - 19:10

Discussion

19:10 - 19:15

Closing remarks

Dr. Daniel Castellano, Medical Oncology Department, Hospital Universitario
12 de Octubre, Madrid

Dr. Félix Guerrero, Urology Department, Hospital Universitario 12 de Octubre, Madrid

Secretaría técnica

 **tactics**

 Barcelona · Madrid

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net

SPONSORS

Bronze



Collaborators

Johnson & Johnson

MERCK



Bristol Myers Squibb

AstraZeneca

Avaes



Actividad acreditada con 5 ECMEC's** presenciales y CPE-DPCs por SEAFORMEC SMPAC. La asistencia a la reunión completa es obligatoria para obtener la acreditación. No recibirán los créditos del sistema acreditador ni estudiantes, ni médicos internos residentes, ya que están excluidos del mismo.

Secretaría técnica

 **tactics**

📍 Barcelona · Madrid

☎ 93 451 17 24

✉ info@tacticsmd.net

🌐 www.tacticsmd.net